“These Phase 2a data underscore our belief that SPN-820 has the potential as a novel treatment option for patients with depression, with the opportunity to decrease symptoms quickly and without ...
Effects of UCHL1 on tolerogenic DC maturation and promotion of mregDC-Treg crosstalk to nullify anti–PD-L1 therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its ...
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma Patients with SCLC and progression on ...
— Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight and Metabolic Profile, and Durable Symptom Control, for Up to Four Years of Treatment — In this global, ...
Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform ...
– Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage– BOULDER, Colo.--(BUSINESS ...
Adolescents in a long-term, open-label extension study receiving a twice-daily low dose of repinatrabit achieved clinically meaningful reductions in blood Phe levels at month one of the open-label ...
Almost half of women of reproductive age experience complaints in the days leading up to menstruation. A lot of treatments come with side effects, only provide limited relief, or don't work for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results